The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents based on its more than two decades of mRNA research. Under terms of the ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

CureVac’s first Covid shot used an unmodified version of mRNA, whereas the vaccines from BioNTech/Pfizer and Moderna modified the mRNA. BioNTech generated almost €19 billion last year, almost ...

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately $1.25bn. The deal is aimed at strengthening BioNTech’s research, ...